US Alcohol Policy Alliance

Summary

What do they do? US Alcohol Policy Alliance convenes advocates and researchers, develops public education and helps state networks advance policies intended to reduce alcohol harm. Its current work includes a national prevention strategy, policy conferences, warning-label advocacy and discussion of state alcohol taxes. Our best estimate is about $4.4 million per 10 USA QALYs, using a deliberately small, uncertain contribution to one state-sized tax opportunity rather than crediting the organization with national drinking trends.

Why we’re interested in this organization:

Alcohol pricing has a plausible and empirically supported pathway to lower consumption and some alcohol-related disease mortality.
The organization has moved beyond a volunteer conference model by hiring executive leadership and preparing an explicit national policy strategy.
State networks can create policy scale without treating every resident as a directly served client; all recipient costs are retained in our calculation.

Our main reservations:

No public evidence identifies the next dollar's effect on a specific state's tax, implementation date or population exposure.
Tax studies differ substantially, and some well-controlled analyses find little lasting crash benefit; mortality effects cannot be read directly from sales or meeting attendance.
The most recent located accounts predate the new CEO and larger agenda; the current operating budget, donor restrictions and funding gap remain unverified.

What do you get for your dollar? $4.4M per better life: ten additional quality-adjusted life years in USA. Alcohol-tax disease mortality only.

Conferences, technical assistance, newsletters and policy discussion are services. A funded-to-policy-to-retail-price-to-disease-mortality bridge is required before QALYs. The modeled mortality subset excludes accidents, homicides and most partly attributable disease; no conversion from awareness or tax dollars to health.

1. What do they do?

USAPA translates research into public-health advocacy rather than providing addiction treatment. Its public portfolio includes labeling, alcohol availability and taxation. Its 2024 leadership plan described 15 state alliances, and Mike Marshall's appointment followed in January 2025. The planned September 2026 Advocates Institute is intended to refine a national prevention strategy. At the research date the event was still in the future; attendance and a strategy document are not yet policy implementation or health gains.

2. Monitoring and information sharing

The current podcast index includes a May 2026 discussion of New Mexico's alcohol-tax effort. This demonstrates engagement, not USAPA-caused legislation. The public record supports a live coordination role but not a verified marginal tax opportunity. Beta monitoring should connect staff time and technical assistance to specific policy texts, votes, implementation, beverage prices, cross-border purchases and resident mortality. It should distinguish proposals, defensive victories and enacted changes from policies that would have occurred anyway. Historic state changes listed on the website cannot all be attributed to USAPA.

3. Qualitative assessment

Alcohol taxation is more promising than awareness alone, but the causal effect is not uniform. A New York quasi-experimental study found a 7% decline in alcohol-related disease mortality after a combined beer/spirits increase, while a spirits-only change and small beer-tax reductions had no significant effect. The public abstract was reviewed; the blocked full text was not used to claim a precise transferable coefficient. A Maryland study estimated 3.8% lower alcohol sales after its tax change in an adjusted model, but the unadjusted per-capita ethanol comparison was unchanged and estimates depended on macroeconomic controls. Sales are not QALYs. An Illinois synthetic-control reanalysis found little sustained reduction in alcohol-related fatal crashes, with a temporary interior-county effect consistent with cross-border avoidance. We therefore exclude injury benefits and use a modest, explicitly subjective disease-mortality response.

The central policy package raises actual retail prices by 5% across beverage types. That is not the same as raising an excise-tax rate by 5%; the website's loose tax/consumption claim is not our coefficient. Ten QALYs per avoided disease death allows substantial chronic illness and competing mortality. Abrupt unsupported withdrawal, unsafe substitution, financial hardship and stigmatizing communication are potential harms, not automatically offset by tax revenue.

4. What do you get for your dollar?

Our central cost is $350,000 a year for five years, the upper end of the organization's published operating-budget plan. This is a judgment for present scale, not an observed 2026 expenditure. The model prices every program and overhead dollar while quantifying only a state tax pathway. A hypothetical policy package covers five million residents; a 5% retail-price rise and mortality elasticity of 0.4 imply 2% fewer alcohol-induced deaths before a 25% leakage/erosion adjustment. A 20% incremental coalition policy probability, 5% USAPA contribution and 50% funding additionality yield about 4.0 expected USA QALYs over the cost cohort—roughly $4.4 million per 10 QALYs.

This is an expected value over uncertain outcomes, not a forecast that USAPA will visibly save four QALYs. Favorable combined assumptions produce about $18,000 per 10 QALYs; a deliberately weak scenario exceeds $1 trillion, with explicit zero and negative cases. These are judgments, not confidence intervals. The 2026 training ticket is $145 with conference registration or $190 without, but that fee is neither a full service cost nor a health-effect price. No verified beneficiaries per donor dollar can be inferred from it. State administrative costs, partner effort and household economic burdens are excluded from the donor-cost numerator and remain relevant to social value. Tax receipts are transfers, not health gains; no treatment funded by the proceeds is counted.

Model, assumptions and sensitivity

All recipient costs at a judged $350,000 annual current scale for five years, informed by the published $200,000–350,000 operating plan. Historical IRS expenses are separately disclosed. Tax-only health quantified; not a restricted-program price or full social cost.

The modeled policy population N consists only of residents of 50 states plus DC, so g=1 by construction. N is a subjective successful-policy scale, not measured reach or a headquarters/population-share allocation. Foreign attendees and territorial effects are excluded from credited health while all recipient costs remain.

A=sum(t=1..T)1/(1.03^(L+t)); annual avoided disease deaths=N*d/100000*x*e*k; H=annual avoided deaths*q*A. Q_all=b*(p*a*H-h); Q_USA=g*Q_all. Cost=C*Y; price=10*Cost/Q_USA if positive. Central A=7.8063439787, annual deaths=10.275, H=802.1018438079 before policy/funding attribution. Small support normalization G multiplies both by G/(C*Y), not a scalable guarantee.

C: 350000 USD per recipient year (judgment). Upper end of publicly described $200,000–350,000 annual operating plan, not an observed 2026 expense. Includes new executive leadership, communications, convening and overhead; current accounts missing. Test $250,000–700,000. [usapa-budget-plan] [usapa-ceo]
Y: 5 recipient support years (judgment). Entire five-year recipient operating cohort, not only a tax campaign budget.
N: 5000000 resident population covered by a successful policy package (judgment). One medium-state-equivalent package across the network, not actual wins or all 15 states. Public plan described 15 state alliances; national/state advocacy could support this scale, but the next target docket is unverified. [usapa-budget-plan] [usapa-state-training] [usapa-podcast]
d: 13.7 alcohol-induced deaths per 100,000 residents annually (observed). CDC2024 crude national alcohol-induced rate, excluding accidents and homicides. Applying it to a future policy population is a transfer judgment, not observed state mortality. No 178,000 broader-attributable-death numerator. [usapa-cdc]
x: 0.05 proportional alcohol retail-price increase (judgment). A reasonably material all-beverage policy package. Five percent RETAIL PRICE, not five percent increase in excise-tax rate; tax design and pass-through required to attain it remain unknown.
e: 0.4 absolute disease-mortality elasticity to retail price (judgment). A 5% retail-price rise is assumed to reduce targeted alcohol-induced mortality 2% before leakage. Intentionally modest relative to some historical disease studies, allowing weak heavy-drinker response, confounding and modern transport. Not fitted from the NY study or the charity's website. [usapa-ny-study] [usapa-maryland-study] [usapa-illinois-reanalysis]
k: 0.75 retained policy effect (judgment). Post-price avoidance, cross-border/beverage substitution and subsequent real-value erosion only. Initial pass-through is already included in the actual retail-price increase x and is not discounted again. [usapa-illinois-reanalysis] [usapa-maryland-study]
q: 10 discounted QALYs per averted alcohol-induced death (judgment). Approximately 20 additional life-years at .65 quality discounted 3% gives about 9.7 QALYs, rounded to 10; chronic comorbidity and mortality displacement could make it much lower. Test 3–15.
L: 3 years before first benefit window (judgment). Legislation, implementation and disease-response lag; first counted outcome year is year4.
T: 10 years of retained incremental effect (judgment). Finite window after lag; no lifetime policy permanence or benefits after year13. Public/state baseline adoption and reversal may shorten this window.
p: 0.2 incremental coalition-enabled policy probability (judgment). Twenty percent extra chance of a material package within five years because of the wider coalition's added effort, not probability that any state ever changes a tax. Current political opposition and small central staffing justify wide uncertainty.
a: 0.05 USAPA contribution within additional coalition effect (judgment). Five percent reserves most credit for state/local organizations, elected officials, voters and fiscal pressures. National coordination, convening and communications provide a plausible but unmeasured enabling role. [usapa-institute] [usapa-state-training] [usapa-podcast]
b: 0.5 marginal support additionality (judgment). Half of incremental donor support creates otherwise absent capacity; the balance substitutes conference income, other donors, reserves or public/academic support. No restricted tax-only pathway assumed. [usapa-irs24] [usapa-budget-plan]
g: 1 USA resident share of modeled health (judgment). N is explicitly defined as residents of 50 states plus DC covered by state policy. Thus all modeled outcomes qualify; foreign delegates and territories have no credited health. This does not assert all recipient spending is domestic.
h: 0 other net health harm over five-year cohort, before b (judgment). No other portfolio health credited centrally. Financial hardship, stigma, unsafe substitution or abrupt unassisted withdrawal could create harm; central zero is a judgment and not a proven lower bound.
discount: 0.03 annual outcome discount rate (judgment). Event-year discount; q already discounts life-years after that event.
historicalFullExpenses: [200361,26948,208012] USD for FY2022,2023,2024 (observed). Accrual recipient totals; no additional direct event/rental/gaming/merchandise expense reported netted from revenue. Conference-cycle fluctuations and new CEO make their mean a poor current-cost proxy. [usapa-irs22] [usapa-irs23] [usapa-irs24]

Subjective expected value: one medium-state-equivalent opportunity: Cost: $1.8M; USA QALYs: 4.010509219039689; all-population QALYs: 4.010509219039689. Parameters {"C":350000,"Y":5,"N":5000000,"d":13.7,"x":0.05,"e":0.4,"k":0.75,"q":10,"L":3,"T":10,"p":0.2,"a":0.05,"b":0.5,"g":1,"h":0}; discounted years A=7.80634397866606.

Broader reach, effective policy and strong marginal role: Cost: $1.3M; USA QALYs: 685.9560681318014; all-population QALYs: 685.9560681318014. Parameters {"C":250000,"Y":5,"N":10000000,"d":13.7,"x":0.1,"e":1,"k":0.9,"q":15,"L":1,"T":15,"p":0.4,"a":0.1,"b":0.8,"g":1,"h":0}; discounted years A=11.590228239588424.

Small short-lived policy with little donor leverage: Cost: $3.5M; USA QALYs: 0.000030085015078863834; all-population QALYs: 0.000030085015078863834. Parameters {"C":700000,"Y":5,"N":1000000,"d":13.7,"x":0.02,"e":0.1,"k":0.3,"q":3,"L":5,"T":3,"p":0.05,"a":0.01,"b":0.1,"g":1,"h":0}; discounted years A=2.439985002340943.

Only three years of policy benefit: Cost: $1.8M; USA QALYs: 1.329883020715277; all-population QALYs: 1.329883020715277. Parameters {"C":350000,"Y":5,"N":5000000,"d":13.7,"x":0.05,"e":0.4,"k":0.75,"q":10,"L":3,"T":3,"p":0.2,"a":0.05,"b":0.5,"g":1,"h":0}; discounted years A=2.588580088983507.

Only three QALYs per averted death: Cost: $1.8M; USA QALYs: 1.203152765711907; all-population QALYs: 1.203152765711907. Parameters {"C":350000,"Y":5,"N":5000000,"d":13.7,"x":0.05,"e":0.4,"k":0.75,"q":3,"L":3,"T":10,"p":0.2,"a":0.05,"b":0.5,"g":1,"h":0}; discounted years A=7.80634397866606.

Current recipient scale twice central plan: Cost: $3.5M; USA QALYs: 4.010509219039689; all-population QALYs: 4.010509219039689. Parameters {"C":700000,"Y":5,"N":5000000,"d":13.7,"x":0.05,"e":0.4,"k":0.75,"q":10,"L":3,"T":10,"p":0.2,"a":0.05,"b":0.5,"g":1,"h":0}; discounted years A=7.80634397866606.

No additional policy effect: Cost: $1.8M; USA QALYs: 0; all-population QALYs: 0. Parameters {"C":350000,"Y":5,"N":5000000,"d":13.7,"x":0.05,"e":0.4,"k":0.75,"q":10,"L":3,"T":10,"p":0,"a":0.05,"b":0.5,"g":1,"h":0}; discounted years A=7.80634397866606.

Tax changes no induced-disease mortality: Cost: $1.8M; USA QALYs: 0; all-population QALYs: 0. Parameters {"C":350000,"Y":5,"N":5000000,"d":13.7,"x":0.05,"e":0,"k":0.75,"q":10,"L":3,"T":10,"p":0.2,"a":0.05,"b":0.5,"g":1,"h":0}; discounted years A=7.80634397866606.

No policy benefit and one other QALY net harm: Cost: $1.8M; USA QALYs: -0.5; all-population QALYs: -0.5. Parameters {"C":350000,"Y":5,"N":5000000,"d":13.7,"x":0.05,"e":0.4,"k":0.75,"q":10,"L":3,"T":10,"p":0,"a":0.05,"b":0.5,"g":1,"h":1}; discounted years A=7.80634397866606.

Five other QALYs of net harm: Cost: $1.8M; USA QALYs: 1.5105092190396894; all-population QALYs: 1.5105092190396894. Parameters {"C":350000,"Y":5,"N":5000000,"d":13.7,"x":0.05,"e":0.4,"k":0.75,"q":10,"L":3,"T":10,"p":0.2,"a":0.05,"b":0.5,"g":1,"h":5}; discounted years A=7.80634397866606.

Counterfactual: State advocates, legislators, researchers and fiscal pressures operate without USAPA. Only an incremental coalition-enabled policy chance is counted, with small USAPA contribution and donor/reserve substitution. No nationwide federal tax victory, historic state victory, concurrent treatment revenue or injury effect is credited. Ten years is a judged differential duration, which falls if baseline adoption catches up.

Attribution: p=.20 is incremental coalition policy probability, a=.05 is USAPA's conditional share, and b=.50 is donor additionality. Effective pre-funding policy contribution is 1% of one five-million-resident package. These are explicit opinions supported by network activity, not measured causal rates. Do not sum overlapping state/charity credit.

Exploratory expected-value best estimate with very broad scenarios. It can fail at policy influence, price pass-through, heavy-drinker response, survival or funding additionality. Unknown other portfolio effects mean this is not a proven lower bound. Central number is not donor-ready endorsement.

Sensitivity

At other central assumptions, p*a must exceed 0.0436354 to beat $1 million per 10 QALYs, or 0.4363536 to beat $100,000. Central p*a is .01.
Equivalently, effective incremental coverage N*p*a must exceed about 218,177 residents for $1 million per 10 QALYs, or 2,181,768 for $100,000, before funding additionality. Central is 50,000 residents.
Other net health harm above 8.0210184 QALYs over the five-year cohort erases the central benefit before funding additionality. Such harm is not attenuated by p*a.
Doubling current cost doubles price; q=3 instead of10 makes it 3.33 times worse. Three-year rather than ten-year benefit duration is calculated separately.
Zero additional policy chance or zero disease-mortality response produces no favorable price. Clinical e and policy p/a are separate uncertainties; adopting a policy does not guarantee fewer deaths.
The national crude d=13.7 is not an age-adjusted rate. Actual target-state disease rates, population trends and mortality displacement could materially change health yield.

Unresolved inputs

Current unrestricted operating budget, post-CEO compensation and grants, conference-cycle accruals, cash commitments and next-dollar workplan.
Specific target policy package, state resident population, exact all-beverage tax/pass-through change and plausible baseline enactment/implementation date.
Independent evidence of USAPA's added influence relative to local alliances, voters, fiscal pressure and other advocates.
Transferable heavy-drinker mortality response, age/comorbidity-specific remaining healthy survival, duration of effect, cross-border/substance substitution and harmful financial tradeoffs.

5. Funding and previous grants

The original FY2024 return reports $208,012 expenses, including $65,531 travel, $60,168 equipment rental and $56,425 contract services. It reports zero employees, $204,294 program-service revenue—largely registrations—and $45,196 contributions. Year-end cash was $199,877 and net assets without donor restrictions $202,477; liabilities were $2,500. These figures predate the CEO hire. Independent review and audit were both marked no. The fiscal year is a full 12 months, not a partial startup period.

Original FY2023 and FY2022 accrual expenses were $26,948 and $200,361. All three have no reported netted direct-event, rental, gaming or merchandise cost to restore; their mean is $145,107. This conference-cycle average is not the current recurring budget. The recruitment plan specified a $115,000–130,000 salary range and $200,000–350,000 annual operating budget. Current conference receipts, project grants, staffing commitments and unrestricted reserves need reconciliation before recommending a gift. None of the three returns reports government grants, but national coordination may still replace work paid for by public, academic or partner budgets. The model's 50% additionality is an opinion about that risk, not documented funding room.

Annual expenses

Organization-level spending, including programs, administration and fundraising. The research list averages three comparable, consecutive full fiscal years when available.

FY 2022: $200K; US Alcohol Policy Alliance Inc., EIN 46-5054613, 12-month period, Accrual; original Form 990 full recipient expense including any reported netted direct costs. Source
FY 2023: $27K; US Alcohol Policy Alliance Inc., EIN 46-5054613, 12-month period, Accrual; original Form 990 full recipient expense including any reported netted direct costs. Source
FY 2024: $208K; US Alcohol Policy Alliance Inc., EIN 46-5054613, 12-month period, Accrual; original Form 990 full recipient expense including any reported netted direct costs. Source

6. Sources

FY2024 Form 990, original IRS e-file. US Alcohol Policy Alliance / IRS. Published: not stated; retrieved: 2026-09-13.
FY2023 Form 990, original IRS e-file. US Alcohol Policy Alliance / IRS. Published: not stated; retrieved: 2026-09-13.
FY2022 Form 990, original IRS e-file. US Alcohol Policy Alliance / IRS. Published: not stated; retrieved: 2026-09-13.
Current mission and policy portfolio. US Alcohol Policy Alliance. Published: not stated; retrieved: 2026-09-13.
Executive director recruitment, salary and operating-budget plan. US Alcohol Policy Alliance. Published: 2024-07-15; retrieved: 2026-09-13.
Appointment of Mike Marshall as CEO. US Alcohol Policy Alliance. Published: 2025-01-31; retrieved: 2026-09-13.
Advocates Institute 2026 and planned national strategy. US Alcohol Policy Alliance. Published: not stated; retrieved: 2026-09-13.
The Shift: current state alcohol-tax discussion. US Alcohol Policy Alliance. Published: not stated; retrieved: 2026-09-13.
Alcohol Use: 2024 national mortality data. CDC National Center for Health Statistics. Published: not stated; retrieved: 2026-09-13.
Effects of alcohol taxes on alcohol-related disease mortality in New York, 1969–2006. Delcher, Maldonado-Molina and Wagenaar / Addictive Behaviors. Published: 2012-03-01; retrieved: 2026-09-13.
Do State Excise Taxes Reduce Alcohol-Related Fatal Motor Vehicle Crashes?. McClelland and colleagues / Economic Inquiry. Published: 2019-06-10; retrieved: 2026-09-13.
Maryland 2011 alcohol sales tax and beverage sales. Esser, Waters, Smart and Jernigan / American Journal of Drug and Alcohol Abuse. Published: 2016-04-11; retrieved: 2026-09-13.
Building Statewide Alliances to Reduce Alcohol-Related Harms. Southeast Prevention Technology Transfer Center. Published: 2021-11-18; retrieved: 2026-09-13.